GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensol Biosciences Inc (XKRX:140610) » Definitions » Net Margin %

Ensol Biosciences (XKRX:140610) Net Margin % : -6,401.82% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Ensol Biosciences Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Ensol Biosciences's Net Income for the six months ended in Dec. 2023 was ₩-11,302.1 Mil. Ensol Biosciences's Revenue for the six months ended in Dec. 2023 was ₩176.5 Mil. Therefore, Ensol Biosciences's net margin for the quarter that ended in Dec. 2023 was -6,401.82%.

The historical rank and industry rank for Ensol Biosciences's Net Margin % or its related term are showing as below:

XKRX:140610' s Net Margin % Range Over the Past 10 Years
Min: -6401.82   Med: -1366.61   Max: -498.3
Current: -6401.82


XKRX:140610's Net Margin % is ranked worse than
88.88% of 1025 companies
in the Biotechnology industry
Industry Median: -140.43 vs XKRX:140610: -6401.82

Ensol Biosciences Net Margin % Historical Data

The historical data trend for Ensol Biosciences's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensol Biosciences Net Margin % Chart

Ensol Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -959.84 -1,727.79 -2,657.51 -571.78 -6,401.82

Ensol Biosciences Semi-Annual Data
Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only -959.84 -1,727.79 -2,657.51 -571.78 -6,401.82

Competitive Comparison of Ensol Biosciences's Net Margin %

For the Biotechnology subindustry, Ensol Biosciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ensol Biosciences's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ensol Biosciences's Net Margin % distribution charts can be found below:

* The bar in red indicates where Ensol Biosciences's Net Margin % falls into.



Ensol Biosciences Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Ensol Biosciences's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-11302.099/176.545
=-6,401.82 %

Ensol Biosciences's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-11302.099/176.545
=-6,401.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ensol Biosciences  (XKRX:140610) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Ensol Biosciences Net Margin % Related Terms

Thank you for viewing the detailed overview of Ensol Biosciences's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ensol Biosciences Business Description

Traded in Other Exchanges
N/A
Address
51, Techno 10-ro, Yuseong-gu, Daejeon, KOR, 34036
Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.

Ensol Biosciences Headlines

No Headlines